Kritische 8-K Meldungen
Stammdaten
Unternehmen
| Name | Ultragenyx Pharmaceutical Inc. |
|---|---|
| Ticker | RARE |
| CIK | 0001515673 |
Branche
| SIC-Code | 2834 |
|---|---|
| Beschreibung | Pharmaceutical Preparations |
Wertpapier
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Titel | Ultragenyx Pharmaceutical Inc. |
Status
| Zuletzt geprüft | 2026-03-23 11:05:26.305926 |
|---|
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 673,000,000 | -575,000,000 | -5.83 | 1,532,000,000 | -80,000,000 |
Fondsaktivität (letzte 3 Quartale)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-10 | Parschauer Karah Herdman | Officer, EVP and Chief Legal Officer | Open Market Sale | -3,508 | 22.67 | -79,526.36 | -59,8% | |
| 2026-03-06 | Parschauer Karah Herdman | Officer, EVP and Chief Legal Officer | Open Market Sale | -6,018 | 21.40 | -128,785.20 | -96,8% | |
| 2026-03-03 | Horn Howard | Officer, Chief Financial Officer | Open Market Sale | -1,635 | 22.40 | -36,624.00 | -27,5% | |
| 2026-03-02 | KAKKIS EMIL D | Director, Officer, President & CEO | Open Market Sale | -54,404 | 22.80 | -1,240,411.20 | -932,2% | |
| 2026-03-02 | Crombez Eric | Officer, EVP and Chief Medical Officer | Open Market Sale | -7,029 | 22.80 | -160,261.20 | -120,4% | |
| 2026-03-02 | Horn Howard | Officer, Chief Financial Officer | Open Market Sale | -3,119 | 22.54 | -70,302.26 | -52,8% | |
| 2026-03-02 | Horn Howard | Officer, Chief Financial Officer | Open Market Sale | -5,290 | 22.80 | -120,612.00 | -90,6% | |
| 2026-03-02 | Parschauer Karah Herdman | Officer, EVP and Chief Legal Officer | Open Market Sale | -8,135 | 22.80 | -185,478.00 | -139,4% | |
| 2026-03-02 | Pinion John Richard | Officer, See Remarks | Open Market Sale | -10,029 | 22.80 | -228,661.20 | -171,8% | |
| 2026-03-02 | Huizenga Theodore Alan | Officer, SVP, Chief Accounting Officer | Open Market Sale | -1,632 | 22.80 | -37,209.60 | -28,0% | |
| 2026-03-02 | Harris Erik | Officer, EVP & Chief Commercial Officer | Open Market Sale | -10,539 | 22.80 | -240,289.20 | -180,6% | |
| 2026-03-02 | Crombez Eric | Officer, EVP and Chief Medical Officer | Open Market Sale | -7,029 | 22.80 | -160,261.20 | -120,4% | |
| 2026-02-02 | Horn Howard | Officer, Chief Financial Officer | Open Market Sale | -3,061 | 23.56 | -72,117.16 | -54,2% | |
| 2026-01-02 | Horn Howard | Officer, Chief Financial Officer | Open Market Sale | -3,150 | 22.84 | -71,946.00 | -54,1% | |
| 2025-12-29 | Huizenga Theodore Alan | Officer, SVP, Chief Accounting Officer | Open Market Sale | -85 | 34.38 | -2,922.30 | -2,2% | |
| 2025-12-10 | Horn Howard | Officer, Chief Financial Officer | Open Market Sale | -3,081 | 36.38 | -112,086.78 | -84,2% | |
| 2025-10-13 | Horn Howard | Officer, Chief Financial Officer | Open Market Sale | -7,942 | 31.51 | -250,252.42 | -188,1% | |
| 2025-09-18 | Huizenga Theodore Alan | Officer, SVP, Chief Accounting Officer | Open Market Sale | -64 | 29.17 | -1,866.88 | -1,4% | |
| 2025-09-12 | Parschauer Karah Herdman | Officer, EVP and Chief Legal Officer | Open Market Sale | -2,450 | 31.17 | -76,366.50 | -57,4% | |
| 2025-09-12 | Parschauer Karah Herdman | Officer, EVP and Chief Legal Officer | Open Market Sale | -2,450 | 31.17 | -76,366.50 | -57,4% | |
| 2025-09-05 | Huizenga Theodore Alan | Officer, SVP, Chief Accounting Officer | Open Market Sale | -84 | 31.39 | -2,636.76 | -2,0% | |
| 2025-06-20 | Sanders Corazon (Corsee) D. | Director | Open Market Sale | -2,405 | 37.39 | -89,922.95 | -67,6% | |
| 2025-06-20 | Sanders Corazon (Corsee) D. | Director | Open Market Sale | -2,405 | 37.39 | -89,922.95 | -67,6% | |
| 2025-05-05 | Crombez Eric | Officer, EVP and Chief Medical Officer | Open Market Sale | -520 | 39.24 | -20,404.80 | -15,3% | |
| 2025-05-05 | Crombez Eric | Officer, EVP and Chief Medical Officer | Open Market Sale | -520 | 39.24 | -20,404.80 | -15,3% | |
| 2025-04-21 | Crombez Eric | Officer, EVP and Chief Medical Officer | Open Market Sale | -242 | 35.11 | -8,496.62 | -6,4% | |
| 2025-04-21 | Crombez Eric | Officer, EVP and Chief Medical Officer | Open Market Sale | -242 | 35.11 | -8,496.62 | -6,4% |
Top-Fondshalter (aktuelles Quartal)
Keine Fondsdaten für das aktuelle Quartal vorhanden.